Comparison
N-Acetyl Cysteine vs PT-141
Side-by-side of N-Acetyl Cysteine and PT-141. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
N-Acetyl Cysteine
NAC supplement benefits cover glutathione synthesis, liver and antioxidant support, and hangover recovery. Evidence strongest at 1200-2400 mg/day.
PT-141
PT-141 peptide (bremelanotide, Vyleesi): MC4R agonist for libido and erectile dysfunction. 1.75 mg subcutaneous, 30 to 60 min onset, 2 to 4 h half-life.
Effects at a glance
N-Acetyl Cysteine
- •Replenishes intracellular glutathione by supplying cysteine, the rate-limiting amino acid for synthesis
- •First-line antidote for acetaminophen toxicity, restoring hepatic glutathione before fulminant injury occurs
- •Reduces sputum viscosity in chronic bronchitis and COPD at 600 to 1200 mg/day over months
- •Modest symptom reductions in OCD and trichotillomania at 1200 to 2400 mg/day across small RCTs
- •Mixed evidence for psychiatric adjunct use in bipolar depression and schizophrenia negative symptoms
- •Inhaled forms can trigger bronchospasm in active asthma; oral use is the standard biohacker route
PT-141
- •Cyclic 7-amino-acid synthetic peptide and melanocortin receptor agonist (MC4R-preferring)
- •FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder in pre-menopausal women
- •Acts centrally on hypothalamic sexual-desire circuits rather than peripherally on vasculature
- •On-demand dosing: subcutaneous 1.75 mg approximately 45 minutes before sexual activity
- •Common adverse effects: nausea (~40%), flushing, headache, injection-site reactions, hyperpigmentation
- •Off-label male ED use is documented but not FDA approved; mechanism is distinct from PDE5 inhibitors
Side-by-side
| Attribute | N-Acetyl Cysteine | PT-141 |
|---|---|---|
| Category | supplement | peptide |
| Also known as | NAC | Bremelanotide, Vyleesi |
| Half-life (hr) ↗ | 5.6 | 2.7 |
| Typical dose (mg) ↗ | 1200 | 1.75 |
| Dosing frequency | 1 to 3 times daily, split dosing preferred | as needed (max once per 24 hours, max 8 per month) |
| Routes | oral, iv | subcutaneous |
| Onset (hr) | 1 | 0.75 |
| Peak (hr) | 2 | 1.5 |
| Molecular weight | 163.19 | 1025.18 |
| Molecular formula | C5H9NO3S | C50H68N14O10 |
| Mechanism | Deacetylated to cysteine, the rate-limiting precursor for glutathione synthesis; also directly scavenges reactive oxygen species and modulates glutamate signaling. | Synthetic agonist of melanocortin receptors with preference for MC4R, expressed in hypothalamic and limbic circuits regulating sexual motivation. Engages central pathways distinct from peripheral PDE5-mediated vasodilation. |
| Legal status | OTC in most jurisdictions; restricted periods in US history (FDA reclassified 2022) | Prescription only as Vyleesi; FDA-approved 2019 for HSDD in pre-menopausal women. Compounded versions sold off-label for male sexual function are research-use-only grey market. |
| WADA status | allowed | allowed |
| DEA / Rx | OTC supplement (US, post-2022); Rx indications also exist (acetaminophen overdose, mucolytic) | Rx only (not a controlled substance) for the FDA-approved Vyleesi formulation |
| Pregnancy | Used clinically in pregnancy for specific indications; consult clinician | Not recommended; contraindicated during pregnancy per Vyleesi label |
| CAS | 616-91-1 | 189691-06-3 |
| PubChem CID | 12035 | 9941379 |
| Wikidata | Q413299 | Q422059 |
Safety profile
N-Acetyl Cysteine
Common side effects
- sulfur-like taste or odor
- nausea
- flatulence
- diarrhea
Contraindications
- active asthma attack (inhaled form can trigger bronchospasm)
- known NAC hypersensitivity
Interactions
- nitroglycerin: potentiates vasodilation, risk of hypotension and headache(moderate)
- activated charcoal: reduces NAC absorption when used for acetaminophen overdose(moderate)
- anticoagulants: theoretical additive antiplatelet effect at high doses(minor)
PT-141
Common side effects
- nausea (~40%)
- flushing
- headache
- injection-site reactions
- hyperpigmentation (focal, gums, face, breasts)
- transient blood pressure increase (~6 mmHg systolic)
Contraindications
- uncontrolled hypertension
- established cardiovascular disease
- pregnancy
- naltrexone co-administration (reduces opioid efficacy due to MC receptor crosstalk)
Interactions
- naltrexone (oral): bremelanotide reduces oral naltrexone exposure significantly; avoid co-administration(major)
- antihypertensives: transient BP rise after bremelanotide can offset BP control(moderate)
- PDE5 inhibitors (sildenafil, tadalafil): no documented adverse interaction; mechanisms are non-overlapping(minor)
Which Should You Take?
N-Acetyl Cysteine comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC, oral dosing, with a Tier-A outcome catalogued. PT-141 is the right call when one of the conditionals below applies.
- → If your priority is healthspan extension, pick N-Acetyl Cysteine.
- → If your priority is post-training recovery, pick N-Acetyl Cysteine.
- → If your priority is sexual function, pick PT-141.
- → If your priority is libido, pick PT-141.
Edge case: If you want to avoid research-only / gray-market sourcing, N-Acetyl Cysteine is the more accessible choice.
Default choice: N-Acetyl Cysteine. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for PT-141 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between N-Acetyl Cysteine and PT-141?
N-Acetyl Cysteine and PT-141 differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, N-Acetyl Cysteine or PT-141?
N-Acetyl Cysteine half-life is 5.6 hours; PT-141 half-life is 2.7 hours.
Can you stack N-Acetyl Cysteine with PT-141?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper